Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment

NCT02585895 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02585895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02585895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
December 21, 2015
Completion date
January 20, 2017
Enrollment
39 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia